WO2009010707A1 - Injectable pharmaceutical compositions containing panthenol - Google Patents
Injectable pharmaceutical compositions containing panthenol Download PDFInfo
- Publication number
- WO2009010707A1 WO2009010707A1 PCT/GB2007/050406 GB2007050406W WO2009010707A1 WO 2009010707 A1 WO2009010707 A1 WO 2009010707A1 GB 2007050406 W GB2007050406 W GB 2007050406W WO 2009010707 A1 WO2009010707 A1 WO 2009010707A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- injection
- dexpanthenol
- panthenol
- injectable pharmaceutical
- use according
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
Definitions
- This invention relates to injectable pharmaceutical compositions containing panthenol and their use in the alleviation of inflammation and pain in joints affected by traumatic arthritis.
- Pain or loss of movement in joints is a common occurrence for those who have suffered damage to cartilage, bone surfaces or ligaments, particularly among the elderly.
- Standard methods of treatment include the administration of corticosteroids by injection into the site of the inflammation.
- relief tends to be temporary and long term use carries a number of contraindications.
- Pantothenic acid sometimes known as vitamin B5
- Pantothenic acid has been used as a dietary supplement and for treatment of bronchial asthma, hay-fever, sinusitis and neurodermatitis.
- pantothenic acid salts may be used in an injectable formulation for treatment of joint pain.
- panthenol the alcohol derivative of pantothenic acid
- panthenol is of value in reducing pain and inflammation when injected into or adjacent to an affected joint.
- panthenol in the preparation of a injectable pharmaceutical composition for administration by injection into a joint, or into a body region closely adjacent to the joint, for alleviation of inflammation or pain caused by traumatic arthritis.
- the alcohol is optically active and the dextro-rotatory isomer dexpanthenol is the preferred active agent.
- Dexpanthenol is commercially available in forms approved by the European Pharmacopiea. There is no evidence of toxicity associated with the ingestion of panthenol. Dexpanthenol has rarely been associated with contact dermatitis when applied topically, and pain, numbness and difficulty breathing following injection.
- the injectable composition contains a dose of at least about 250 mg, typically at least about 400 mg of dexpanthenol, preferably at least about 500 mg, more preferably at least about 800 mg, and most suitably about 1000 mg i.e. about 1 gram of dexpanthenol.
- the exact dosage will vary with the condition treated, and the age and condition of the patient. A course of injections may be required, given at intervals of about one week. Reduced inflammation and increased freedom of movement is usually noticeable shortly after administration and a review of the response can be made after about a week of treatment. A second dose can then be given if necessary.
- an injectable pharmaceutical composition is prepared by dissolving the panthenol in a suitable solvent, e.g. water, and injecting the solution into, or closely adjacent to, the affected joint.
- a suitable solvent e.g. water
- the initial treatment may cause some pain and it may, therefore, be desirable to co-administer a local anaesthetic, such as bupivicaine or lignocaine, either as a separate injection at the same time or shortly before the injection of the panthenol, or as a coformulation with panthenol.
- physiologically active materials may be co-administered, if desired, e.g. cysteine or glucosamine.
- the injectable pharmaceutical compositions of this invention may be used in the treatment of several painful conditions associated with inflammation or reduced movement of joints. Although some relief may be obtained using the present invention to treat rheumatoid arthritic conditions, such treatment is not recommended because it will be only temporary due to the immune reaction cause of the disease.
- the main aim of the invention is to treat traumatic arthritic conditions, which are normally found to occur in only one joint at a time. Examples include tennis elbow, housemaid's knee, frozen shoulder, inflamed knee joints, ankle joints and hip joints and back pain associated with inflammation or restricted movement in the spinal vertebrae, such as posttraumatic spondylitis.
- the injectable pharmaceutical composition may be injected into the capsule of the joint by intra-articular injection.
- the injectable pharmaceutical composition may also be administered closely adjacent to the joint, but outside the capsule so that it can diffuse into the capsule, by peri-articular injection.
- injection outside the capsule is preferred, to avoid the risk of damage to the joint; this also enables the use of large dose (and hence large volume) injections which would be difficult to accommodate in small joints.
- Facet joints requiring injection are identified by an area of extreme tenderness in the area of pain and spasm in the patient's back. A needle inserted at right angles into this area will be located in or close to the facet joint. The solution does not have to be injected directly into the joint as it will diffuse into it; injections into and around the joint are equally effective.
- An injection into the region of a joint may be within about 5, 4, 3, 2 or 1 cm of the capsule of the joint, or closer.
- a dose of about 2 mis of an aqueous solution containing about 500 mg of dexpanthenol can be effective.
- the dose contains about 1000 mg of dexpanthenol, for example, as about 4 mis of an aqueous solution containing about 250 mg/ml.
- a programme of injections is generally desirable in which dosages similar to that indicated above are given at intervals of a few days to a few weeks.
- When administering an injection of 2 mis containing 500 mg dexpanthenol if the injection is painful, it may be appropriate to discontinue the injection at delivery of 1 ml, providing 250 mg of dexpanthenol, and repeat the dose at a later time.
- the preferred 1 ,000 mg dose may be given as, for example, two consecutive 500 mg doses.
- a suitable injectable formulation comprises 1000 mg of dexpanthenol and 1-10 mg of bupivicaine, for example, as 4 mis of an aqueous solution containing 250 mg/ml. dexpanthenol and 1 ml of a solution containing 1 mg of bupivicaine or 2 ml of a 0.5% solution of bupivicaine.
- the dose of bupivicaine can be adjusted dependin on the reaction of indivaula patiens to the injection.
- the bupivicaine, or other local anaesthetic can be administered as a separate injection immediately before an injection of dexpanthenol.
- Example 1 62 patients (26 men; 33 women) aged 21 to 85 years were treated for traumatic inflammatory conditions. The patients were administered one or more intra-articular or peri-articular injections, ie into the inflamed joint or nearby area, of dexpanthenol in combination with a long acting local anaesthetic [4 ml of an aqueous solution of dexpanthenol Ph Eur (providing 1000 mg of dexpanthenol); 1 ml of 0.1 % bupivacaine (providing 1 mg of bupivacaine)].
- a long acting local anaesthetic [4 ml of an aqueous solution of dexpanthenol Ph Eur (providing 1000 mg of dexpanthenol); 1 ml of 0.1 % bupivacaine (providing 1 mg of bupivacaine)].
- Example 1 The cohort of patients assessed in Example 1 primarily reported back pain to the test physician. Treatment of some patients who reported specific joint pain is summarised below.
- Bepanthene is a aqueous solution containing 250 mg/ml of dexpanthenol Ph Eur, 4 mis bepanthene provides 1000 mg dexpanthenol
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Rheumatology (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
Abstract
Use of panthenol in the preparation of a pharmaceutical composition for administration by intraarticular or periarticular injection to a joint which is inflamed or painful due to traumatic arthritis.
Description
INJECTABLE PHARMACEUTICAL COMPOSITIONS CONTAINING PANTHENOL
This invention relates to injectable pharmaceutical compositions containing panthenol and their use in the alleviation of inflammation and pain in joints affected by traumatic arthritis.
Pain or loss of movement in joints is a common occurrence for those who have suffered damage to cartilage, bone surfaces or ligaments, particularly among the elderly. Standard methods of treatment include the administration of corticosteroids by injection into the site of the inflammation. However, relief tends to be temporary and long term use carries a number of contraindications.
Pantothenic acid (sometimes known as vitamin B5) and its salts have been used as a dietary supplement and for treatment of bronchial asthma, hay-fever, sinusitis and neurodermatitis.
European Patent No. 1 276 477 discloses that pantothenic acid salts may be used in an injectable formulation for treatment of joint pain.
It has now been found that panthenol, the alcohol derivative of pantothenic acid, is of value in reducing pain and inflammation when injected into or adjacent to an affected joint.
According to the present invention there is provided use of panthenol in the preparation of a injectable pharmaceutical composition for administration by injection into a joint, or into a body region closely adjacent to the joint, for alleviation of inflammation or pain caused by traumatic arthritis.
The alcohol is optically active and the dextro-rotatory isomer dexpanthenol is the preferred active agent. Dexpanthenol is commercially available in forms approved by the European Pharmacopiea. There is no evidence of toxicity associated with the ingestion of panthenol. Dexpanthenol has rarely been associated with contact dermatitis when applied topically, and pain, numbness and difficulty breathing following injection.
Suitably the injectable composition contains a dose of at least about 250 mg, typically at least about 400 mg of dexpanthenol, preferably at least about 500 mg, more preferably at least about 800 mg, and most suitably about 1000 mg i.e. about 1 gram of dexpanthenol. The exact dosage will vary with the condition treated, and the age and condition of the patient. A course of injections may be required, given at intervals of about one week. Reduced inflammation and increased freedom of movement is usually noticeable shortly after administration and a review of the response can be made after about a week of treatment. A second dose can then be given if necessary.
Conveniently, an injectable pharmaceutical composition is prepared by dissolving the panthenol in a suitable solvent, e.g. water, and injecting the solution into, or closely adjacent to, the affected joint. The initial treatment may cause some pain and it may, therefore, be desirable to co-administer a local anaesthetic, such as bupivicaine or lignocaine, either as a separate injection at the same time or shortly before the injection of the panthenol, or as a coformulation with panthenol.
Other physiologically active materials may be co-administered, if desired, e.g. cysteine or glucosamine.
The injectable pharmaceutical compositions of this invention may be used in the treatment of several painful conditions associated with inflammation or reduced movement of joints. Although some relief may be obtained using the present invention to treat rheumatoid arthritic conditions, such treatment is not recommended because it will be only temporary due to the immune reaction cause of the disease. The main aim of the invention is to treat traumatic arthritic conditions, which are normally found to occur in only one joint at a time. Examples include tennis elbow, housemaid's knee, frozen shoulder, inflamed knee joints, ankle joints and hip joints and back pain associated with inflammation or restricted movement in the spinal vertebrae, such as posttraumatic spondylitis.
For large joints, i.e. most joints except vertebrae, the injectable pharmaceutical composition may be injected into the capsule of the joint by intra-articular injection.
The injectable pharmaceutical composition may also be administered closely adjacent to the joint, but outside the capsule so that it can diffuse into the capsule, by
peri-articular injection. For small joints, especially the vertebrae, injection outside the capsule is preferred, to avoid the risk of damage to the joint; this also enables the use of large dose (and hence large volume) injections which would be difficult to accommodate in small joints.
Facet joints requiring injection are identified by an area of extreme tenderness in the area of pain and spasm in the patient's back. A needle inserted at right angles into this area will be located in or close to the facet joint. The solution does not have to be injected directly into the joint as it will diffuse into it; injections into and around the joint are equally effective.
An injection into the region of a joint may be within about 5, 4, 3, 2 or 1 cm of the capsule of the joint, or closer.
A dose of about 2 mis of an aqueous solution containing about 500 mg of dexpanthenol can be effective. Preferably the dose contains about 1000 mg of dexpanthenol, for example, as about 4 mis of an aqueous solution containing about 250 mg/ml. A programme of injections is generally desirable in which dosages similar to that indicated above are given at intervals of a few days to a few weeks. When administering an injection of 2 mis containing 500 mg dexpanthenol, if the injection is painful, it may be appropriate to discontinue the injection at delivery of 1 ml, providing 250 mg of dexpanthenol, and repeat the dose at a later time. Similarly, the preferred 1 ,000 mg dose may be given as, for example, two consecutive 500 mg doses.
Reduced inflammation and increased freedom of movement is usually noticeable within 48 hours from the initial injection. Using the 1000 mg dose, patients have reported an estimated 80% reduction of pain after the first injection.
To provide short-term pain relief during the course of the injection, so as to negate any pain due to the effect of the injection itself, a suitable injectable formulation comprises 1000 mg of dexpanthenol and 1-10 mg of bupivicaine, for example, as 4 mis of an aqueous solution containing 250 mg/ml. dexpanthenol and 1 ml of a solution containing 1 mg of bupivicaine or 2 ml of a 0.5% solution of bupivicaine. The
dose of bupivicaine can be adjusted dependin on the reaction of indivaula patiens to the injection.
Alternatively the bupivicaine, or other local anaesthetic can be administered as a separate injection immediately before an injection of dexpanthenol.
Test Data
Example 1 62 patients (26 men; 33 women) aged 21 to 85 years were treated for traumatic inflammatory conditions. The patients were administered one or more intra-articular or peri-articular injections, ie into the inflamed joint or nearby area, of dexpanthenol in combination with a long acting local anaesthetic [4 ml of an aqueous solution of dexpanthenol Ph Eur (providing 1000 mg of dexpanthenol); 1 ml of 0.1 % bupivacaine (providing 1 mg of bupivacaine)].
In terms of pain relief following injection, efficacy outcome of the treatment is shown in the table below:
Site of complaint n* Outcome
Improved Temporarily No Worsened Not n (%) improved change n (%) reported n (%) n (%) n (%)
Back (post-traumatic 54 30 (55.6) 6 (11.1 ) 6 (11.1 ) 3 (5.6) 9 (16.7) spondylitis)
Hip 22 9 (40.9) 4 (18.2) 2 (9.1 ) 2 (9.1 ) 5 (22.7)
Knee 8 5 (62.5) 0 (0) 1 (12.5) 0 (0) 2 (25.0)
Other 14 5 (35.7) 3 (21.4) 1 (7.1 ) 1 (7.1 ) 4 (28.6)
Total 98 49 (50.0) 13 (13.2) 10 (10.2) 6 (6.1 ) 20 (20.4)
* Some patients reported more than one site
In this cohort of patients, 87% of patients complained of back pain, which was often accompanied by pain in other joints or sites. Where reported, three-quarters of all
patients benefited from pain relief, while less than 10% said that their condition had worsened. Several patients mentioned that they experienced improvement after the initial injection, which continued to improve with time. Although, in most cases, the complaint was reported as 'improved' only, there was indication that several patients had considerable benefit from the treatment.
From case notes of the 62 patients, injections of dexpanthenol in combination with bupivicaine into the joint or nearby area was generally safe and well tolerated. Five (8%) of the 62 patients reported adverse events, including numbness and injection site pain, which resolved with time.
Injection of facet joints has previously almost invariably been done using MRI to ensure exact placing of the needle. However in the above testing it was found that facet joints are easily treated by injection without the use of MRI. By palpating the patient's back in the area of pain and spasm, there is often an area of extreme tenderness about 5 cms from the midline, indicating the site of the inflamed facet joints. If a needle is inserted at right angles into this area, it will be located in or exceedingly close to the facet joint. The dexpanthenol solution does not have to be injected directly into the joint, as it will diffuse into the joint from an injection adjacent to it; both are equally effective.
Example 2
The cohort of patients assessed in Example 1 primarily reported back pain to the test physician. Treatment of some patients who reported specific joint pain is summarised below.
Bepanthene is a aqueous solution containing 250 mg/ml of dexpanthenol Ph Eur, 4 mis bepanthene provides 1000 mg dexpanthenol
An injection of 2 mis of 0.5% bupivicaine provides 10 mg bupivicaine
Hip pain
Injection - 4 ml bepanthene, 2 ml of 0.5% bupivacaine
Patient 1 - hip - 1 injection - "considerable relief" straight away.
Patient 2 - left hip - 1 injection - "immediate improvement"
Patient 3 - right hip - 1 injection - "hip improving, no sudden change after injection"
Patient 4 - right hip - 1 injection - " hip better"
Tennis elbow
Injection - 1-2 ml bepanthene, 0.5-1 ml of 0.5% bupivacaine
Patient 1 - both elbows injected - better
Patient 2 - 4 injections - full recovery
Patient 3 - right elbow - 2 injections - better
Patient 4 - right elbow - 2 injections - better
Shoulder pain
Injection into Capsule - 4 ml bepanthene, 2 ml of 0.5% bupivacaine
Injection adjacent Capsule (into Tendon) - 1-2 ml bepanthene, 0.5-1 ml of 0.5% bupivacaine
Patient 1 - left shoulder - 2 injections - improved
Patient 2 - 12 injections over 6 months - 95% improvement
Ankle Pain Injection - 4 ml bepanthene, 2 ml of 0.5% bupivacaine
Patient 1 - 1 injection - better
Patient 2 - 2 injections - better
Patient 3 - 1 injection - better
Patient 4 - 9 injections over 2 - months 90% improvement
Knee Pain
Injection - 4 ml bepanthene, 2 ml of 0.5% bupivacaine
Patient 1 - right knee 3 injections, left knee 2 injections - " knees have been feeling a lot better"
Claims
1. Use of panthenol in the preparation of a pharmaceutical composition for administration by intraarticular or periarticular injection of a joint which is inflamed or painful due to traumatic arthritis.
2. Use according to claim 1 , wherein panthenol is used as dexpanthenol.
3. Use according to claim 1 or 2, wherein the injectable pharmaceutical composition comprises an aqueous solution of panthenol.
4. Use according to any one of the preceding claims, wherein the injectable pharmaceutical composition includes a co-formulated local anaesthetic.
5. Use according to any one of claims 1 to 4, wherein a local anaesthetic is coadministered with panthenol in a separate injection.
6. Use according to any one of claims 1 to 5, wherein the injectable pharmaceutical composition is a formulation comprising at least 250 mg of dexpanthenol.
7. Use according to any one of claims 1 to 6, wherein the injectable pharmaceutical composition is a formulation comprising about 1000 mg of dexpanthenol.
8. Use according to any one of claims 1 to 6, wherein the injectable pharmaceutical composition is a formulation comprising 250 - 1000 mg of dexpanthenol and 1 - 10 mg bupivivaine.
9. Use according to any one of claims 1 to 8 wherein the medicament is for intraarticular or periarticular injection of elbow, shoulder, knee, ankle, hip and facet joints.
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP07766447A EP2178526A1 (en) | 2007-07-13 | 2007-07-13 | Injectable pharmaceutical compositions containing panthenol |
PCT/GB2007/050406 WO2009010707A1 (en) | 2007-07-13 | 2007-07-13 | Injectable pharmaceutical compositions containing panthenol |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/GB2007/050406 WO2009010707A1 (en) | 2007-07-13 | 2007-07-13 | Injectable pharmaceutical compositions containing panthenol |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2009010707A1 true WO2009010707A1 (en) | 2009-01-22 |
Family
ID=39386394
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/GB2007/050406 WO2009010707A1 (en) | 2007-07-13 | 2007-07-13 | Injectable pharmaceutical compositions containing panthenol |
Country Status (2)
Country | Link |
---|---|
EP (1) | EP2178526A1 (en) |
WO (1) | WO2009010707A1 (en) |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4619829A (en) * | 1982-11-16 | 1986-10-28 | Georges Motschan | Utilization of a single vitamin or a combination of various vitamins |
EP0214947A1 (en) * | 1985-07-15 | 1987-03-18 | S.S.M. International Chemical Company Limited | Antalgic and anti-inflammatory composition for the treatment of arthrosis |
CH682803A5 (en) * | 1993-02-11 | 1993-11-30 | Georg Dr Kunovits | Use of panthenol, pantetheine or pantothenate, capable of stimulating endogeneous cortico-steroid biosynthesis - in compsn. for treating e.g. bronchial asthma, rheumatism, hay fever or osteoarthritis |
WO2000072823A1 (en) * | 1999-05-27 | 2000-12-07 | Euroceltique S.A. | Preparations for the application of anti-inflammatory agents |
WO2001019359A2 (en) * | 1999-09-16 | 2001-03-22 | Britannia Pharmaceuticals Limited | Medicaments containing pantothenic acid for the treatment of inflammatory joint disease |
WO2001041783A1 (en) * | 1999-12-09 | 2001-06-14 | Bruce Levin | Methods and compositions for treatment of inflammatory disease |
-
2007
- 2007-07-13 WO PCT/GB2007/050406 patent/WO2009010707A1/en active Application Filing
- 2007-07-13 EP EP07766447A patent/EP2178526A1/en not_active Withdrawn
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4619829A (en) * | 1982-11-16 | 1986-10-28 | Georges Motschan | Utilization of a single vitamin or a combination of various vitamins |
EP0214947A1 (en) * | 1985-07-15 | 1987-03-18 | S.S.M. International Chemical Company Limited | Antalgic and anti-inflammatory composition for the treatment of arthrosis |
CH682803A5 (en) * | 1993-02-11 | 1993-11-30 | Georg Dr Kunovits | Use of panthenol, pantetheine or pantothenate, capable of stimulating endogeneous cortico-steroid biosynthesis - in compsn. for treating e.g. bronchial asthma, rheumatism, hay fever or osteoarthritis |
WO2000072823A1 (en) * | 1999-05-27 | 2000-12-07 | Euroceltique S.A. | Preparations for the application of anti-inflammatory agents |
WO2001019359A2 (en) * | 1999-09-16 | 2001-03-22 | Britannia Pharmaceuticals Limited | Medicaments containing pantothenic acid for the treatment of inflammatory joint disease |
WO2001041783A1 (en) * | 1999-12-09 | 2001-06-14 | Bruce Levin | Methods and compositions for treatment of inflammatory disease |
Non-Patent Citations (1)
Title |
---|
MARY EAGLESON ED - EAGLESON M (TRANSLATOR): "Concise Encyclopedia Chemistry", CONCISE ENCYCLOPEDIA CHEMISTRY. ABC CHEMIE (ORIGINAL GERMAN TITEL 1993), BERLIN : WALTER DE GRUYTER, DE, 1 January 1994 (1994-01-01), pages 775 - 776, XP002161980, ISBN: 978-3-11-011451-5 * |
Also Published As
Publication number | Publication date |
---|---|
EP2178526A1 (en) | 2010-04-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2017202343B2 (en) | Neosaxitoxin combination formulations for prolonged local anesthesia | |
JP5909750B2 (en) | Low dose intravenous acetaminophen | |
EP2381956B1 (en) | Treatment of soft tissue injury using hyaluronic acid and botulinum toxin | |
US20140142073A1 (en) | Aqueous based capsaicinoid formulations and methods of manufacture and use | |
Krenzel et al. | Posterior capsular injections of ropivacaine during total knee arthroplasty: a randomized, double-blind, placebo-controlled study | |
CA2735834C (en) | Composition comprising ibuprofen and paracetamol to treat pain caused by osteoarthritis and rheumatoid arthritis | |
KR20070003995A (en) | Compositions with reduced hepatotoxicity | |
KR20080031950A (en) | Synergistic time-delaying agent for local anesthetic | |
US4312865A (en) | Medication having penetration through cutaneous surfaces into articular and muscular areas | |
US20030125303A1 (en) | Transdermal formulation for repair and maintenance of connective tissue | |
SK164695A3 (en) | Use of ropivacaine in the manufacture of a pharmaceutical agent with analgetic effect with minimal motor blockade | |
EP2178526A1 (en) | Injectable pharmaceutical compositions containing panthenol | |
Chen et al. | Efficacy and safety of an intra-operative intra-articular magnesium/ropivacaine injection for pain control following total knee arthroplasty | |
JPH061721A (en) | Pain treating agent and pain mitigating activity potentiator | |
GB2355930A (en) | Injection of pantothenic acid for relief of pain in joints | |
CN117797155B (en) | Pharmaceutical formulation against ketamine toxicity | |
Tennant Jr | (−)-α-Acetylmethadol for treatment of chronic pain patients who abuse opioids | |
Khuvtsagaan et al. | Comparison of Local Infiltration Analgesia With Femoral Nerve Block for Pain Treatment Outcome of Total Knee Arthroplasty | |
htS Reserved | New Molecular Entities | |
Van Den Eeden et al. | Local Infiltration Analgesia with Anterior Total Hip Arthroplasty under General Anaesthesia does Reduce Opioids Consumption and Pain: A Randomized, Double-Blind, Placebo-Controlled Trial Involving 106 Patients |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 07766447 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2007766447 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2010105055 Country of ref document: RU Ref document number: 1017/DELNP/2010 Country of ref document: IN |